The synergistic effect of panobinostat (LBH589) with melphalan or doxorubicin on multiple myeloma cells; rationale for the use of combination regimens in myeloma patients

Leukemia Research

Volumn 35, Issue 3, 2011, Pages 295-296

  Terpos, Evangelos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Histone deacetylase inhibitors; Multiple myeloma; Panobinostat (LBH589); Therapy

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; MELPHALAN; PANOBINOSTAT; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; DISEASE MODEL; DRUG EFFICACY; DRUG POTENTIATION; EDITORIAL; HUMAN; IN VITRO STUDY; MONOTHERAPY; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANIMALS; DOXORUBICIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MELPHALAN; MICE; MULTIPLE MYELOMA;

EID: 79952100628     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.10.019     Document Type: Editorial

References (12)

1. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
2. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007, 8:286-298.
3. Glozak M.A., Seto E. Histone deacetylases and cancer. Oncogene 2007, 26:5420-5432.
4. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 2009, 280:233-241.
5. Ellis L., Pan Y., Smyth G.K., George D.J., McCormack C., Williams-Truax R., et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008, 14:4500-4510.
6. Kastritis E., Zervas K., Symeonidis A., Terpos E., Delimbassi S., Anagnostopoulos N., et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009, 23:1152-1157.
7. Badros A., Burger A.M., Philip S., Niesvizky R., Kolla S.S., Goloubeva O., et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009, 15:5250-5257.
8. Maiso P., Carvajal-Vergara X., Ocio E.M., López-Pérez R., Mateo G., Gutiérrez N., et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006, 66:5781-5789.
9. Catley L., Weisberg E., Kiziltepe T., Tai Y.T., Hideshima T., Neri P., et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006, 108:3441-3449.
10. Kaiser M., Lamottke B., Mieth M., Jensen M.R., Quadt C., Garcia-Echeverria C., et al. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. Eur J Haematol 2010, 84:337-344.
11. Ocio E.M., Vilanova D., Atadja P., Maiso P., Crusoe E., Fernández-Lázaro D., et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 2010, 95:794-803.
12. Sanchez E., Shen J., Steinberg J., Li M., Wang C., Bonavida B., et al. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leuk Res 2011, 35:373-379.